Literature DB >> 6652020

Inhibition of cell-cycle progression by acute treatment with various degrees of hypoxia: modifications induced by low concentrations of misonidazole present during hypoxia.

E O Pettersen, T Lindmo.   

Abstract

The effect on cell-cycle progression in various phases of the cell cycle caused by an acute exposure to hypoxia in absence and presence of misonidazole (MISO) was investigated. Exponentially growing and synchronized cells of the human line NHIK 3025 were exposed to different degrees of hypoxia for a short period (1.5 or 3 h). The cell-cycle progression was studied both during and after hypoxia by flow-cytometric recording of DNA-histograms from treated and untreated cells. The rate of cell-cycle progression was reduced during hypoxia only if the O2-concentration was below 1000 ppm. The inhibition was phase specific with a strong effect in S (reduced DNA-synthesis), and a specific cell-cycle inhibition in late G1, probably at the G1/S-border. For cells inhibited (or arrested for extreme hypoxia) at the G1/S-border, the cell-cycle progression changed back to normal shortly after aerobic conditions were re-established. For cells rendered hypoxic and inhibited during S, hypoxia exerted a lasting effect expressed by a low cell-cycle progression rate even after aerobic conditions were re-established. This effect was strongly dependent on both the degree and the duration of the hypoxic treatment. The presence of a low concentration of MISO (0.05 mM) during hypoxia did not affect the cell-cycle progression during hypoxia at any O2-concentration. For cells rendered hypoxic during S, however, MISO (0.05 mM) counteracted the lasting effect of hypoxia for all concentrations of O2 where this lasting effect was observed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6652020      PMCID: PMC2011554          DOI: 10.1038/bjc.1983.271

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  24 in total

1.  Hypoxic sensitizers: radiobiological studies at the cellular level.

Authors:  E J Hall; L Roizin-Towle
Journal:  Radiology       Date:  1975-11       Impact factor: 11.105

2.  The effect of prolonged hypoxia on growth and viability of Chinese hamster cells.

Authors:  R Born; O Hug; K R Trott
Journal:  Int J Radiat Oncol Biol Phys       Date:  1976 Jul-Aug       Impact factor: 7.038

3.  X-ray inactivation of human cells in tissue culture under aerobic and extremely hypoxic conditions in the presence and absence of TMPN.

Authors:  E O Pettersen; R Oftebro; T Brustad
Journal:  Int J Radiat Biol Relat Stud Phys Chem Med       Date:  1973-09

4.  The effect of hypoxia on the growth and radiation response of mammalian cells in culture.

Authors:  J S Bedford; J B Mitchell
Journal:  Br J Radiol       Date:  1974-10       Impact factor: 3.039

5.  Cell-cycle analysis in 20 minutes.

Authors:  H A Crissman; R A Tobey
Journal:  Science       Date:  1974-06-21       Impact factor: 47.728

6.  Plateau phase in growth induced by hypoxia.

Authors:  C J Koch; J Kruuv; H E Frey; R A Snyder
Journal:  Int J Radiat Biol Relat Stud Phys Chem Med       Date:  1973-01

Review 7.  Cyclic x-ray responses in mammalian cells in vitro.

Authors:  W K Sinclair
Journal:  Radiat Res       Date:  1968-03       Impact factor: 2.841

8.  Cell respiration as a function of oxygen tension.

Authors:  J W Boag
Journal:  Int J Radiat Biol Relat Stud Phys Chem Med       Date:  1970

9.  Serum concentration: effects on cycle and x-ray sensitivity of mammalian cells.

Authors:  G M Hahn; M A Bagshaw
Journal:  Science       Date:  1966-01-28       Impact factor: 47.728

10.  Biochemical balance and syncronized cell cultures.

Authors:  E C Anderson; D F Petersen; R A Tobey
Journal:  Nature       Date:  1967-09-02       Impact factor: 49.962

View more
  9 in total

1.  Prolyl hydroxylase PHD3 enhances the hypoxic survival and G1 to S transition of carcinoma cells.

Authors:  Heidi Högel; Krista Rantanen; Terhi Jokilehto; Reidar Grenman; Panu M Jaakkola
Journal:  PLoS One       Date:  2011-11-08       Impact factor: 3.240

Review 2.  Tumor hypoxia: its impact on cancer therapy.

Authors:  J E Moulder; S Rockwell
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

3.  Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status.

Authors:  T G Graeber; J F Peterson; M Tsai; K Monica; A J Fornace; A J Giaccia
Journal:  Mol Cell Biol       Date:  1994-09       Impact factor: 4.272

4.  Cell cycle distribution of hypoxia and progression of hypoxic tumour cells in vivo.

Authors:  L Webster; R J Hodgkiss; G D Wilson
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

5.  The retinoblastoma protein-associated cell cycle arrest in S-phase under moderate hypoxia is disrupted in cells expressing HPV18 E7 oncoprotein.

Authors:  O Amellem; J A Sandvik; T Stokke; E O Pettersen
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

6.  Obesity-induced kidney injury is attenuated by amelioration of aberrant PHD2 activation in proximal tubules.

Authors:  Koji Futatsugi; Hirobumi Tokuyama; Shinsuke Shibata; Makiko Naitoh; Takeshi Kanda; Hitoshi Minakuchi; Shintaro Yamaguchi; Koichi Hayashi; Yoji Andrew Minamishima; Motoko Yanagita; Shu Wakino; Hiroshi Itoh
Journal:  Sci Rep       Date:  2016-11-09       Impact factor: 4.379

Review 7.  Tumor Hypoxia as a Barrier in Cancer Therapy: Why Levels Matter.

Authors:  Tord Hompland; Christina Sæten Fjeldbo; Heidi Lyng
Journal:  Cancers (Basel)       Date:  2021-01-28       Impact factor: 6.639

8.  Regulation of cell proliferation under extreme and moderate hypoxia: the role of pyrimidine (deoxy)nucleotides.

Authors:  O Amellem; M Löffler; E O Pettersen
Journal:  Br J Cancer       Date:  1994-11       Impact factor: 7.640

9.  Hypoxia inducible prolyl hydroxylase PHD3 maintains carcinoma cell growth by decreasing the stability of p27.

Authors:  Heidi Högel; Petra Miikkulainen; Lucia Bino; Panu M Jaakkola
Journal:  Mol Cancer       Date:  2015-07-30       Impact factor: 27.401

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.